Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | MicrobiomeTrials
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2025-09-26Est. Completion: 2029-06-01
Enrollment target: 630 participants
Locations
Research Site, Fullerton, California, United States
Research Site, Glendale, California, United States
Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, Orange, California, United States
Research Site, San Francisco, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Orange City, Florida, United States
Research Site, St. Petersburg, Florida, United States
Research Site, Tamarac, Florida, United States
Research Site, Atlanta, Georgia, United States
Research Site, Locust Grove, Georgia, United States
Research Site, Effingham, Illinois, United States
Research Site, Niles, Illinois, United States
Research Site, Peoria, Illinois, United States
Research Site, Largo, Maryland, United States
Research Site, Boston, Massachusetts, United States
Research Site, Grand Rapids, Michigan, United States
Other microbiome trials you might be interested in